Never Run Out Of Buyers To Sell To.

We develop injectable decoy biotherapeutics for the selective and quick removal of harmful circulating antibodies from blood. Our peptide-based decoys can be specifically adapted for vector-neutralizing antibodies in gene therapy, or drug-neutralizing anti-drug antibodies in enzyme- and factor replacement therapies (e.g. glycogen storage diseases, hemophilia & other rare conditions).
Annual Revenue$1M to $5M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.